Cognitive Enhancement Peptides: Focus & Neuroprotection

Medical Disclaimer: The information in this article is intended for educational and research purposes only. Peptides discussed here are research chemicals. Dihexa and Cerebrolysin require special caution — they have potent neurological effects and limited human safety data. This content does not constitute medical advice. Always consult a neurologist or qualified healthcare provider before beginning any nootropic peptide protocol. Peptok.ai does not endorse self-administration of any research chemical.

The brain is the most complex and least understood organ in the body — and it's increasingly the target of sophisticated peptide research. Unlike stimulants (which simply force neurotransmitter release) or traditional nootropics (which often work via non-specific mechanisms), neurological peptides can interact with specific growth factors, neuroprotective pathways, and neuroplasticity mechanisms at a fundamental level.

This guide covers the most researched cognitive peptides in 2026: from the well-established Soviet-era peptides Semax and Selank, to cutting-edge compounds like Dihexa and P21, to the mitochondria-derived MOTS-c. Each operates on distinct neurobiological pathways, enabling precise stacking strategies for different cognitive goals.

---

The Neurobiology of Cognitive Enhancement

Before diving into specific compounds, understanding the major pathways involved helps in choosing and combining cognitive peptides:

• BDNF (Brain-Derived Neurotrophic Factor): The primary neurotrophic growth factor. Supports survival of existing neurons, promotes growth of new synapses (synaptogenesis), and is essential for long-term potentiation (LTP) — the cellular mechanism of memory formation. Low BDNF is associated with depression, cognitive decline, and Alzheimer's.
• NGF (Nerve Growth Factor): Supports cholinergic neurons in the basal forebrain — the neurons most affected in Alzheimer's disease. Promotes neurite outgrowth and synaptic density.
• NMDA receptor activity: The N-methyl-D-aspartate receptor is central to learning, memory, and synaptic plasticity. Too little: cognitive impairment. Too much: excitotoxicity.
• HPA axis regulation: The hypothalamic-pituitary-adrenal axis governs cortisol. Chronic stress (and elevated cortisol) is one of the most powerful drivers of cognitive impairment. Some cognitive peptides work primarily by normalizing HPA axis activity.
• Neurogenesis: New neuron formation in the hippocampus continues throughout adult life and is critical for memory, mood regulation, and cognitive reserve.

---

Semax: ACTH-Derived Cognitive Enhancer

Semax (MEHFPGP) is a synthetic heptapeptide analog of the ACTH(4-7) fragment. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, Semax has been approved in Russia for the treatment of stroke, TBI, cognitive disorders, and ADHD since 1996. Its safety and efficacy profile is among the best-documented of all cognitive peptides.

Mechanisms of Action

• BDNF upregulation: Semax's most well-characterized mechanism is rapid and potent upregulation of BDNF and its precursor proBDNF in the hippocampus and frontal cortex. Studies show increases of 100–800% in BDNF expression within hours of administration.
• NGF increase: Simultaneously increases Nerve Growth Factor and its receptor TrkA expression.
• Dopaminergic modulation: Influences dopamine, serotonin, and enkephalin systems, contributing to mood stabilization and focused attention.
• Neuroprotection: Protects neurons against hypoxia (oxygen deprivation) and excitotoxic damage — the primary use in stroke recovery in Russia.
• Anti-inflammatory: Reduces neuroinflammation markers including IL-6 in the brain.

NA-Semax and NA-Semax Amidate

Two enhanced versions of Semax exist:

• NA-Semax (N-Acetyl Semax): N-acetylation at the N-terminus extends bioavailability and potency. Generally considered 2–3x more potent per mcg than standard Semax.
• NA-Semax Amidate: Further modification with an amide group at the C-terminus. Considered the most potent and stable form. Used at lower doses.

Dosing Protocol

• Standard Semax: 200–900 mcg intranasally per day (nasal spray is the most practical route)
• NA-Semax: 100–500 mcg intranasally per day
• NA-Semax Amidate: 50–200 mcg intranasally per day
• Frequency: Once or twice daily (morning doses for acute focus; some use PM dose for overnight neuroplasticity)
• Cycle: 2–4 weeks on, 1–2 weeks off is a conservative approach. Some users run extended protocols of 3–6 months without cycling.
• Storage: Refrigerate; stable for ~2–4 weeks reconstituted

Best for: Acute cognitive focus, stroke recovery, ADHD-like attention deficits, general cognitive enhancement, neuroprotection.

---

Selank: The Anxiolytic Nootropic

Selank (TKPRPGP) is a synthetic heptapeptide analog of the immunomodulatory peptide Tuftsin, combined with a stabilizing sequence. Like Semax, it was developed at the Institute of Molecular Genetics and is approved in Russia for anxiety disorders and cognitive impairment.

Mechanisms of Action

• GABAergic modulation: Selank has anxiolytic properties comparable to benzodiazepines (in animal models) but without sedation, dependency, or withdrawal. It appears to modulate GABA-A receptor activity and enhance GABAergic neurotransmission.
• BDNF upregulation: Like Semax, increases BDNF expression, contributing to learning and memory effects.
• Enkephalin regulation: Inhibits enkephalin-degrading enzymes, increasing the brain's natural opioid tone — contributing to mood improvement and reduced anxiety without euphoria or addiction risk.
• IL-6 and immune modulation: Has documented immunomodulatory effects — increases IL-2, IFN-γ, and regulates T-cell activity. Particularly interesting for cognitive impairment associated with chronic illness or infection (including long COVID).
• Serotonin system: Normalizes serotonin metabolism in the frontal cortex and hippocampus.

NA-Selank Amidate

The enhanced version — N-Acetyl Selank Amidate — has extended bioavailability and is considered more potent than standard Selank. Particularly popular for anxiety-driven cognitive impairment.

Dosing Protocol

• Standard Selank: 250–750 mcg intranasally per day
• NA-Selank Amidate: 100–400 mcg intranasally per day
• Frequency: Once or twice daily (particularly effective for morning anxiety that impairs cognition)
• Cycle: 2–4 weeks on, 1 week off; or as-needed for acute anxiety situations

Best for: Anxiety-related cognitive impairment, PTSD, generalized anxiety, stress-induced memory problems, immune dysregulation, cognitive enhancement in anxious individuals.

---

Dihexa: Neuroplasticity and Memory Augmentation

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide developed at Washington State University by researchers Joe Harding and Juan Sanchez-Santed. It is derived from angiotensin IV and is arguably the most potent neuroplasticity compound discovered to date.

Mechanisms of Action

• HGF/c-Met pathway: Dihexa's primary mechanism involves potent agonism of the HGF (hepatocyte growth factor) receptor c-Met. This signaling cascade drives neurite outgrowth, synaptogenesis, and dendritic spine formation — physically increasing synaptic connectivity.
• Long-term potentiation (LTP): Dramatically enhances LTP in the hippocampus. Animal studies show Dihexa improves performance in memory tasks equivalent to or exceeding established cognitive enhancers by 7–8 orders of magnitude (meaning it's extraordinarily potent at very low doses).
• Alzheimer's model improvement: Reduces cognitive deficits in rodent models of Alzheimer's disease by promoting synaptic growth in damaged neural circuits.

Important Cautions

Dihexa is one of the most powerful neuroplasticity compounds known, but this power comes with significant unknowns:

• Long half-life: Estimated half-life of weeks to months — effects may persist long after discontinuation
• Limited human safety data: Almost all data is from rodent studies. Human pharmacokinetics and safety profile are not well established.
• HGF/c-Met activation concerns: HGF/c-Met is involved in cell growth broadly — some researchers have expressed concern about potential tumor-promoting effects with long-term use, though this has not been demonstrated with Dihexa specifically
• Pro-social effects: Some users report marked changes in social behavior and emotional processing — not always predictable

Dosing Protocol

• Topical (preferred): 1–4 mg applied to skin (inner wrist, neck) daily; transdermal absorption is effective
• Intranasal: 1–2 mg per dose
• Oral: 4–10 mg (lower bioavailability)
• Frequency: Due to its long half-life, many protocols use Dihexa 3x/week or less
• Cycle: Short cycles (2–4 weeks) with extended off periods are strongly recommended

---

Bioregulator Peptides: Pinealon and Cortagen

Bioregulator peptides (khavinson peptides) are extremely short peptides (2–4 amino acids) originally developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike most research peptides, several have undergone extensive human clinical trials in Russia.

Pinealon (Glu-Asp-Arg)

Pinealon is a tripeptide that targets the brain and retinal tissue. It promotes neuronal activity in the pineal gland and cortex.

• Mechanisms: Regulates melatonin synthesis, neuroprotective gene expression, reduces oxidative stress in neurons, promotes neuronal survival and function
• Clinical data: Khavinson's studies show improvements in cognitive function and neuroprotection in aged individuals; significant reduction in oxidative markers in brain tissue
• Dose: 5–10 mg oral daily (often taken sublingually), 10–20 day course repeated quarterly
• Best for: Age-related cognitive decline, sleep/circadian regulation, retinal protection

Cortagen (Ala-Glu-Asp-Pro)

Cortagen is a tetrapeptide targeting the cortex. It promotes repair and normalization of cortical neurons.

• Mechanisms: Normalizes gene expression in cortical neurons, promotes neuronal metabolism, reduces inflammation in cortical tissue
• Clinical data: Russian clinical trials show improvement in cognitive function following stroke and TBI; anti-aging effects on cortical function in elderly subjects
• Dose: 5–10 mg subcutaneous or intramuscular, 10-day courses repeated 1–2x per year
• Best for: Post-stroke recovery, TBI rehabilitation, age-related cognitive protection

---

P21: Neurogenesis Induction

P21 (NAPVSIPQ) is a peptide derived from Activity-Dependent Neuroprotective Protein (ADNP). ADNP is one of the most abundant proteins in the brain and is essential for fetal brain development — mutations cause Helsmoortel-Van der Aa syndrome (autism-like condition).

Mechanisms

• Directly promotes hippocampal neurogenesis — growth of new neurons
• Activates SIRT1, a longevity-associated deacetylase that regulates neuronal gene expression
• Neuroprotective against excitotoxic and oxidative damage
• Shown to improve cognitive performance in Alzheimer's models, Down syndrome models, and normal aging rodents
• May upregulate doublecortin (DCX), a marker of adult neurogenesis

Dosing Protocol

• Dose: 50–100 mcg intranasally per day
• Frequency: Daily, or 5 days on / 2 days off
• Cycle: 4–12 weeks; limited long-term human data
• Best for: Neurogenesis, memory, age-related cognitive decline, recovery from neurological injury

---

Cerebrolysin: The Neurotrophic Complex

Cerebrolysin is a peptide complex derived from purified pig brain proteins, containing a mixture of neurotrophic peptides including BDNF, CNTF, NGF, and others, along with amino acids. It's not a single compound but a complex mixture — more similar to a brain-derived neurotrophic extract than a synthetic peptide.

Clinical Evidence

Cerebrolysin has extensive human clinical trial data (primarily European and Asian), including:

• Randomized controlled trials in Alzheimer's disease showing cognitive improvement
• Acute ischemic stroke recovery studies
• TBI rehabilitation protocols
• Vascular dementia treatment studies

Dosing Protocol

• Standard therapeutic: 5–10 mL intramuscular or intravenous, daily for 10–20 days
• Enhancement protocol: 5 mL intramuscular 2–3x/week for 4–8 weeks
• IV (maximum benefit): 10–30 mL in 100 mL saline over 30–60 minutes, daily for 10–20 days
• Availability: Widely available in Europe, Asia, Mexico; not FDA-approved in US but importable for personal use in some circumstances

---

Stacking for Specific Cognitive Goals

Focus and Executive Function Stack

• Core: NA-Semax Amidate 100–200 mcg intranasal AM
• Add: NA-Selank 200 mcg intranasal if anxiety is a factor
• Cycle: 3 weeks on, 1 week off
• Rationale: Semax drives BDNF and dopaminergic tone for focus; Selank reduces anxiety-driven prefrontal impairment

Memory and Neuroplasticity Stack

• Core: Dihexa 1–2 mg topical 3x/week
• Add: Semax 400 mcg intranasal daily (BDNF support)
• Add: P21 50 mcg intranasal daily
• Cycle: 3–4 weeks on, 2 weeks off (due to Dihexa's long half-life)
• Rationale: Dihexa drives synaptogenesis via HGF/c-Met; P21 adds neurogenesis; Semax amplifies BDNF

Neuroprotection and Anti-Aging Stack

• Core: Cerebrolysin 5 mL IM, 3x/week for 4 weeks
• Add: Pinealon 10 mg oral daily during Cerebrolysin cycle
• Add: Semax 300 mcg intranasal daily
• Repeat: Quarterly cycles
• Rationale: Cerebrolysin provides multi-factor neurotrophic support; Pinealon targets circadian and oxidative neuroprotection; Semax maintains BDNF elevation between intensive cycles

Anxiety-Driven Cognitive Impairment Stack

• Core: NA-Selank Amidate 200–400 mcg intranasal daily
• Add: Semax 300 mcg intranasal (separate from Selank administration if possible)
• Consider: Cortagen 5 mg SubQ for cortical normalization (10-day cycle quarterly)
• Rationale: Selank directly addresses anxiety → cognitive impairment loop; Semax rebuilds BDNF eroded by chronic stress

---

Safety and Considerations

---

Final Thoughts

Cognitive peptides represent some of the most exciting research in neuropharmacology. Unlike traditional stimulants or even established nootropics, compounds like Semax, Selank, and Dihexa work at the level of fundamental neuroplasticity mechanisms — potentially improving the brain's actual capacity rather than just temporarily boosting neurotransmitter levels.

The Soviet-era peptides (Semax, Selank, the bioregulators) have the most compelling human safety and efficacy data. More recent Western compounds like Dihexa and P21 have more limited human data despite extraordinary animal study results. Approach accordingly: proven compounds for ongoing protocols, experimental compounds for cautious, monitored short cycles.

As with all peptide research, work with a knowledgeable neurologist or physician — especially when targeting complex neurological conditions. These are powerful tools deserving careful, informed application.